loader2
Login Open ICICI 3-in-1 Account
Text Size
Text to Speech
Color Contrast
Pause Animations

Latest Rapid Results

Open Free Trading Account Online with ICICIDIRECT
+91

Q3FY26 Quarterly Result Announced for Steel Exchange India Ltd.

Iron & Steel Products company Steel Exchange India announced Q3FY26 results

  • Revenue from operations: Rs 24,035.05 lakh against Rs 32,750.5 lakh during Q3FY25, change -27%.
  • PAT: Rs 227.9 lakh against Rs 1,586.47 lakh during Q3FY25, change -86%.
  • EPS: Rs 0.02 for Q3FY26.

Result PDF

Q3FY26 Quarterly Result Announced for Elantas Beck India Ltd.

Specialty Chemicals company Elantas Beck India announced Q3FY26 results

  • Revenue from operations: Rs 21,519.94 lakh against Rs 19,697.1 lakh during Q3FY25, change 9%.
  • PBT: Rs 5,284.22 lakh against Rs 3,997.71 lakh during Q3FY25, change 32%.
  • PAT: Rs 3,936.57 lakh against Rs 2,974.24 lakh during Q3FY25, change 32%.
  • EPS: Rs 49.66 for Q3FY26.

Result PDF

Q3FY26 Quarterly Result Announced for KSB Ltd.

Compressors & Pumps company KSB announced Q3FY26 results

  • Revenue from operations: Rs 7,840 million against Rs 7,264 million during Q3FY25, change 8%.
  • PBT: Rs 1,082 million against Rs 980 million during Q3FY25, change 10%.
  • PAT: Rs 810 million against Rs 731 million during Q3FY25, change 11%.
  • EPS: Rs 4.65 for Q3FY26.

Result PDF

Q4CY25 Quarterly Result Announced for Sanofi India Ltd.

Pharmaceuticals company Sanofi India announced Q4CY25 results

  • Revenue from operations: Rs 4,198 million against Rs 5,149 million during Q4CY24, change -18%.
  • PBT: Rs 830 million against Rs 1,222 million during Q4CY24, change -32%.
  • PAT: Rs 617 million against Rs 913 million during Q4CY24, change -32%.
  • EPS: Rs 26.79 for Q4CY25.

Result PDF

Q4CY25 Quarterly Result Announced for Sanofi Consumer Healthcare India Ltd.

Pharmaceuticals company Sanofi Consumer Healthcare India announced Q4CY25 results

  • Revenue at Rs 2,510 million, a growth of 47%.
  • Domestic Sales grew by 23%.
  • Export Sales grew by 9.3x due to low base.
  • Profit after tax for Q4CY25 reached Rs 665 million, an increase of 50% on a YoY basis.

Himanshu Bakshi, Managing Director, Sanofi Consumer Healthcare India, said: “This quarter’s performance emphasizes the strength of our core portfolio and the disciplined execution of our growth agenda. Our domestic business has delivered healthy double-digit growth for two successive quarters, complemented by strong contributions from our export markets. The recognition we’ve earned for elevating our brands and championing the issues that matter to consumers is a testament to our teams’ commitment. As we continue to invest in our people and our brands, we remain focused on reinforcing our brand fundamentals and driving operational excellence to unlock the next phase of sustainable growth. Guided by science and driven by purpose, we remain committed to simplifying self-care, making it more accessible and effective for every consumer.”

Amit Jain, Chairman, Sanofi Consumer Healthcare India, said: “Our full-year performance reflects the strength of our strategy and the disciplined execution by our teams. By driving sustained growth, deepening penetration of our portfolio and accelerating digital transformation, we delivered meaningful outcomes for all our stakeholders. Our strong financial performance this year enables us to reward shareholders with a healthy dividendof Rs 75 per share.”

Result PDF

Disclaimer – I ICICI Securities Ltd. ( I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is acting as a distributor to solicit bond related products. All disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein mentioned are solely for informational and educational purpose.
Download App

Download Our App

Get it on google Play Store Download on the App Store
market app